PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia, research operations in Boston and a regional office in Singapore.
Exegenesis Bio, founded in 2019 with strong investor backing, has built a broad pipeline of gene therapies in difficult to treat disease areas. The company has developed proprietary viral capsid discovery and synthetic gene regulation platforms. The company’s AAvarta®, rAAV capsid in silico evolution platform, combined with its Constellation®, computer assisted synthetic DNA augmentation platform create a proprietary innovation engine to drive development of the company’s next generation gene therapy pipeline.
Exegenesis Bio has raised over $120 M during the past two years, has hired over 100 scientific and technical operations staff and is investing to build fully integrated research, development and GMP-grade, commercial-scale manufacturing capabilities. The company expects to dose the first patient in its next generation Type I Spinal Muscular Atrophy (SMA) AAV gene therapy program by the end of the year in China and is preparing to file two Global INDs in the first half of 2022.
“Exegenesis Bio has grown at a rapid pace during the past two years. Our pipeline is progressing very well and we expect to initiate clinical development of three programs during the next year. This is the right time for us to establish our US organization as we prepare to double in size during the next year. Many of our new roles will be based in Philadelphia and Boston. This is a very exciting time for our company,” states Zhenhua Wu, CEO, Exegenesis Bio.
About Exegenesis Bio
Exegenesis Bio is a global gene therapy company developing medicines to treat a wide range of genetic diseases in areas of high unmet need.
Founded in 2019 with strong financial backing, Exegenesis Bio has developed a rich pipeline of early to clinical stage programs in Eye, CNS and Liver-directed genetic diseases. The company is building fully integrated, research, development and manufacturing capabilities to support its programs.
Exegenesis Bio has recruited a globally experienced management team with extensive experience in building and scaling biotechnology and gene therapy companies. The company has raised over $120 M since beginning operations in 2019.